VVOS

Vivos Therapeutics, Inc.

0.18 USD

Last updated Sep 4, 19:31 UTC

Yesterday HIGH

$0.18

Yesterday LOW

$0.17

52w HIGH

$4.62

52w LOW

$0.16

EPS

-0.31

PE

-0.58

Next Earnings

Nov 18, 2026

Overview News Insider Transactions Government Trades Fundamentals

Vivos Therapeutics, Inc. stock is down -47.47% since 30 days ago. The next earnings date is Nov 18, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 5 September’s closed higher than August.

Benzinga Insights

Tue Aug 4, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday's after-market session. American Well (NYSE:AMWL) stock rose 12.76% to $11.75. The market value of their outstanding
Benzinga Newsdesk

Tue Aug 4, 2026

Vivos Therapeutics Has Been Granted U.S. Patent Number 12,697,190 Titled "VIBRATIONAL ORAL APPLIANCE WITH MANDIBULAR ADVANCEMENTS"

https://x.com/PatentGrants/status/2084730195765002647https://ppubs.uspto.gov/pubwebapp/external.html?q=(12697190).pn
Benzinga Newsdesk

Mon Aug 3, 2026

Vivos Therapeutics' Bradford Amman Resigns As CFO; Roman Franklin Appointed As Chief Financial Officer

-SEC Filing
Benzinga Insights

Tue Jun 30, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-market session. The company's market cap stands at $4.4 million. Vivos Therapeutics (NASDAQ:VVOS) shares increased
Benzinga Newsdesk

Tue Jun 30, 2026

Vivos Therapeutics Announces Its Treatment With ITS FDA-Cleared Vida Oral Appliance Demonstrates Enhancement In Insomnia Severity In 100% Of Patients In Trial

Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing‑related sleep disorders such as
Benzinga Insights

Tue Jun 23, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-market session. The market value of their outstanding shares is at $8.8 million. Mobile-health Network (NASDAQ:MNDR)
Benzinga News-desk

Mon Jun 22, 2026

Vivos Extends Streeterville Financing Deal Through Aug. 31, Reaffirms Plan To Convert Up To $4.5M Debt Into Preferred And Common Stock

Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated
Benzinga Newsdesk

Thu Jun 11, 2026

Vivos Therapeutics Announces Intent To File Registration For Proposed Rights Offering

Key Terms of the Proposed Rights OfferingExercise price: Each right is expected to entitle the holder to purchase one share of Vivos common stock at an exercise price that is the greater of $1.25 per share or 20% above
Benzinga Newsdesk

Wed Jun 10, 2026

Vivos Therapeutics shares are trading lower. The company announced a collaboration agreement with South Palm Cardiovascular Associates to support the formation and operation of AIM Florida.
Benzinga Newsdesk

Wed Jun 10, 2026

Vivos Therapeutics Partners With South Palm Cardiovascular Associates To Form, Operate Physician-Aligned Management Services Organization AIM Florida

Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health

Bradford K Amman, Principal Accounting Officer

Fri Jul 31, 2026

VVOS Recent Insider Trades and Stock Chart

150,000 shares awarded
Bradford K Amman, Principal Accounting Officer

Fri Jul 31, 2026

VVOS Recent Insider Trades and Stock Chart

250,000 shares awarded